Efficacy and tolerability of a fixed dose combination of methylcobalamin and pregabalin in the management of painful neuropathy

Prabhoo, Ram; Panghate, Atul; Dewda, Raj Pavitra; More, Balaji; Prabhoo, Tanay; Rana, Rajiv

doi:10.4103/1947-2714.103336

Cited by 9 publications

(6 citation statements)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A post-marketing surveillance study of efficacy and tolerability of daily dosing of 75 mg pregabalin and 750 µg methylcobalamin orally for the treatment of painful peripheral neuropathy was conducted by Prabhoo et al In this multicenter study, data of 1327 subjects were obtained, and the analysis showed a reduction in the Visual Analog Scale (VAS) score for pain by the 4th week in 74% of subjects, with 82% of subjects reporting good to excellent tolerability. Furthermore, concomitant medication use fell from 30% to 8% between weeks two and four of the study, primarily relating to analgesic or muscle-relaxing drugs [ 21 ].…”

Section: Resultsmentioning

confidence: 99%

B12 as a Treatment for Peripheral Neuropathic Pain: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Neuropathic pain describes a range of unpleasant sensations caused by a lesion or disease of the somatosensory nervous system. The sensations caused by neuropathic pain are debilitating and improved treatment regimens are sought in order to improve the quality of life of patients. One proposed treatment for neuropathic pain is vitamin B12, which is thought to alleviate pain by a number of mechanisms including promoting myelination, increasing nerve regeneration and decreasing ectopic nerve firing. In this paper, the evidence for B12 as a drug treatment for neuropathic pain is reviewed. Twenty four published articles were eligible for inclusion in this systematic review in which a range of treatment regimens were evaluated including both B12 monotherapy and B12 in combination with other vitamins or conventional treatments, such as gabapentinoids. Overall, this systematic review demonstrates that there is currently some evidence for the therapeutic effect of B12 in the treatment of post-herpetic neuralgia (level II evidence) and the treatment of painful peripheral neuropathy (level III evidence).

show abstract

Section: Resultsmentioning

confidence: 99%

B12 as a Treatment for Peripheral Neuropathic Pain: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The subjects were asked to report any adverse events experienced at any point in the study. We used the Physicians Global Assessment of Tolerability to Therapy (PGATT) form [ 49 – 51 ]. Subjects used a five-point scale to assess tolerability from “worst tolerability” (which corresponds to patients’ not being able to tolerate the drug at all) to “excellent tolerability” (which corresponds to no adverse effects and the patient being able to tolerate the drug excellently).…”

Section: Methodsmentioning

confidence: 99%

Examining the effect ofWithania somniferasupplementation on muscle strength and recovery: a randomized controlled trial

Wankhede¹,

Langade

Joshi³

et al. 2015

Journal of the International Society of Sports Nutrition

View full text Add to dashboard Cite

BackgroundWithania somnifera (ashwagandha) is a prominent herb in Ayurveda. This study was conducted to examine the possible effects of ashwagandha root extract consumption on muscle mass and strength in healthy young men engaged in resistance training.MethodsIn this 8-week, randomized, prospective, double-blind, placebo-controlled clinical study, 57 young male subjects (18–50 years old) with little experience in resistance training were randomized into treatment (29 subjects) and placebo (28 subjects) groups. Subjects in the treatment group consumed 300 mg of ashwagandha root extract twice daily, while the control group consumed starch placebos. Following baseline measurements, both groups of subjects underwent resistance training for 8 weeks and measurements were repeated at the end of week 8. The primary efficacy measure was muscle strength. The secondary efficacy measures were muscle size, body composition, serum testosterone levels and muscle recovery. Muscle strength was evaluated using the 1-RM load for the bench press and leg extension exercises. Muscle recovery was evaluated by using serum creatine kinase level as a marker of muscle injury from the effects of exercise.ResultsCompared to the placebo subjects, the group treated with ashwagandha had significantly greater increases in muscle strength on the bench-press exercise (Placebo: 26.4 kg, 95 % CI, 19.5, 33.3 vs. Ashwagandha: 46.0 kg, 95 % CI 36.6, 55.5; p = 0.001) and the leg-extension exercise (Placebo: 9.8 kg, 95 % CI, 7.2,12.3 vs. Ashwagandha: 14.5 kg, 95 % CI, 10.8,18.2; p = 0.04), and significantly greater muscle size increase at the arms (Placebo: 5.3 cm2, 95 % CI, 3.3,7.2 vs. Ashwagandha: 8.6 cm2, 95 % CI, 6.9,10.8; p = 0.01) and chest (Placebo: 1.4 cm, 95 % CI, 0.8, 2.0 vs. Ashwagandha: 3.3 cm, 95 % CI, 2.6, 4.1; p < 0.001). Compared to the placebo subjects, the subjects receiving ashwagandha also had significantly greater reduction of exercise-induced muscle damage as indicated by the stabilization of serum creatine kinase (Placebo: 1307.5 U/L, 95 % CI, 1202.8, 1412.1, vs. Ashwagandha: 1462.6 U/L, 95 % CI, 1366.2, 1559.1; p = 0.03), significantly greater increase in testosterone level (Placebo: 18.0 ng/dL, 95 % CI, -15.8, 51.8 vs. Ashwagandha: 96.2 ng/dL, 95 % CI, 54.7, 137.5; p = 0.004), and a significantly greater decrease in body fat percentage (Placebo: 1.5 %, 95 % CI, 0.4 %, 2.6 % vs. Ashwagandha: 3.5 %, 95 % CI, 2.0 %, 4.9 %; p = 0.03).ConclusionThis study reports that ashwagandha supplementation is associated with significant increases in muscle mass and strength and suggests that ashwagandha supplementation may be useful in conjunction with a resistance training program.

show abstract

“…[10][11][12][13] Saat ini belum terdapat penelitian mengenai pencampuran mekobalamin dengan sediaan parenteral lainnya. Pada observasi terjadi 9 pencampuran sediaan mekobalamin, yaitu dalam ringer laktat 500 cc (3 sediaan), dalam 300 cc ringer laktat (1 sediaan), dan dalam 500 cc ringer laktat (5 sediaan).…”

unclassified

Effect of Pharmaceutical Care in Patients with Cardiovascular Risk in Community

Rochmawati

Queljoe

Dewi

et al. 2014

Indones J Clin Pharm

View full text Add to dashboard Cite

AbstrakPencampuran sediaan parenteral (iv admixture) yang sudah dilaksanakan secara umum di rumah sakit mempunyai kemungkinan terjadinya kegagalan baik berupa inkompatibilitas obat maupun gangguan stabilitas obat. Penelitian ini bertujuan mengetahui angka inkompatibilitas obat dalam pencampuran sediaan parenteral di RSUD Prof. Dr. Margono Soekarjo Purwokerto yang mengalami inkompatibilitas fisika yang teramati secara organoleptis. Penelitian ini merupakan penelitian deskriptif prospektif. Data yang telah dikumpulkan lalu dianalisis secara deskriptif. Dari 667 pencampuran sediaan parenteral di bangsal bedah saraf RSUD Prof. Dr. Margono Soekarjo selama bulan Februari 2010, dapat disimpulkan angka inkompatibilitas potensial sebesar 0,45% dan inkompatibilitas aktual sebesar 2,55%. Inkompatibilitas aktual yang terjadi berupa kristal 0,17%, endapan 0,17%, dan kabut sementara 2,04% pada pencampuran fenitoin dengan NaCl atau ringer laktat. However, it has a possibility of failures, like incompatibilities and changes in drug stabilities. The aim of this study was to determine the rate of drug incompatibilities in mixing parenteral preparations in neurosurgery ward in Prof. Dr. Margono Soekarjo Regional Public Hospital which undergo physical incompatibility observed in organoleptic. This study was a prospective descriptive research for one month period. Data were collected and analyzed descriptively. The results showed that from 667 parenteral admixtures in neurosurgery ward in Prof Dr Margono Soekarjo Hospital in February 2010, there were 0.45% potential incompatibility and 2.55% actual incompatibility happened. Actual incompatibility shown as crystal 0.17%, sediment 0.17%, and 2.04% was non-permanent haze in phenytoin and sodium chloride or ringer lactate admixtures.

show abstract

Efficacy and tolerability of a fixed dose combination of methylcobalamin and pregabalin in the management of painful neuropathy

Cited by 9 publications

References 8 publications

B12 as a Treatment for Peripheral Neuropathic Pain: A Systematic Review

B12 as a Treatment for Peripheral Neuropathic Pain: A Systematic Review

Examining the effect ofWithania somniferasupplementation on muscle strength and recovery: a randomized controlled trial

Effect of Pharmaceutical Care in Patients with Cardiovascular Risk in Community

Contact Info

Product

Resources

About